The median survival period is usually 3-5 years after active treatment. With the emergence of various new therapeutic drugs, the median survival period has been significantly extended, depending on the extent of the disease. It should also be clear that asymptomatic multiple myeloma does not require treatment, and regular review is sufficient, and patients can survive for more than 10 years at this time. Multiple myeloma has many different classifications, as well as many subtypes and different stages. Multiple myeloma is often clinically classified into three different grades, with median survival varying according to the indicators of each risk grade. The median survival is 8-10 years for the low-risk grade, 4-5 years for the intermediate-risk grade, and 3 years for the high-risk grade. However, these are only averages and there is some variation among individuals. The natural course of multiple myeloma patients varies widely, but the progression of the disease can be effectively controlled by aggressive basic therapy, radiotherapy, including targeted therapy, glucocorticoid therapy, and hematopoietic stem cell transplantation. In addition, with the advent of immunotherapy such as immunosuppression, patients’ disease-free survival and overall survival time can be significantly improved. However, it should be noted that if a patient progresses from high-risk asymptomatic multiple myeloma to multiple myeloma, survival may be significantly shorter after aggressive treatment compared to earlier stages.